Xiaobei Zheng

TL;DR: CP therapy was well tolerated and could potentially improve the clinical outcomes through neutralizing viremia in severe COVID-19 cases and the optimal dose and time point, as well as the clinical benefit of CP therapy, needs further investigation in larger well-controlled trials.

TL;DR: CP therapy was welltolerated and could potentially improve the clinical outcomes through neutralizing viremia in severe COVID-19 cases, but the optimal dose and time point, as well as the clinical benefit of CP therapy, needs further investigation in larger well-controlled trials.

TL;DR: In this paper, a production method of virus-inactivated plasma for treating COVID-19 was proposed, which comprises the following steps: (1) collecting convalescent plasma or plasma immune to a Severe Acute Respiratory Syndrome Coronavirus 2 vaccine (SARS-CoV-2 vaccine), and conducting pretreatment; (2) adding methylene blue, and conducting photo-inactivation on the plasma; and (3) conducting labeling and packaging after the plasma passes tests.

TL;DR: In this article, the authors proposed a method for extracting intravenous injection human immunoglobulin from a plasma separation component I and an ion exchange chromatography component III. The method comprises the steps of (1) precipitating F I+III components: dissolving FI+III precipitate in water for injection according to the concentration of 20%(wt), and precipitating impurity protein in F I +III components underthe condition of 50mM sodium caprylate and pH being 4.9; and (2) further refining IgG components by using ion exchange